The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The latest updates in the pre-malignant space: the PROMISE study and the potential of immunotherapy
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest updates in the pre-malignant space. She highlights the PROMISE study (NCT03689595), a screening study for individuals at risk of developing multiple myeloma, as well as the potential of immunotherapy in the treatment of smoldering myeloma. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Last year in ASH, we had daratumumab, which was the Phase III trial, showing us that indeed we can treat early for smoldering myeloma. This year, I’m very excited that we’re presenting the PROMISE study, which is the U.S. screening study for people at risk, meaning people who are African-American or of family history. Of course, there is the late-breaking session from Dr Mariette Mathios, as well as the in vivo CAR-T...
Last year in ASH, we had daratumumab, which was the Phase III trial, showing us that indeed we can treat early for smoldering myeloma. This year, I’m very excited that we’re presenting the PROMISE study, which is the U.S. screening study for people at risk, meaning people who are African-American or of family history. Of course, there is the late-breaking session from Dr Mariette Mathios, as well as the in vivo CAR-T. So we’re now looking at more and more immunotherapy in an earlier setting. And of course, we’re doing the same thing in smoldering myeloma, looking at immunotherapy, whether it’s bispecific or CAR-T therapy in smoldering multiple myeloma. So the idea is, indeed, you can screen early, you can identify who’s at risk and who’s not, and then the people at risk you can intercept early, potentially with immunotherapy, and maybe we are curing patients in the small ring setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
